Different from the principles of traditional drug therapy, gene therapy regulates the expression of specific genes in the human body. Common gene therapy strategies include the introduction of normal genes (gene supplementation therapy), repair of defective genes (gene-editing therapy), and gene replacement therapy. The research of gene therapy is dependent on animal models of gene modification, surgical model, drug induction, and carrier modeling. As an international and innovative CRO platform based on research model animals, Cyagen makes the establishment of gene-edited animal models more efficient through its self-developed TurboKnockoutⓇ technology and CRISPR-Pro technology. In addition, Cyagen can provide surgical disease models and gene therapy vector model construction services.
Service Category |
Case |
Genetic Modification Method |
Rare disease model |
Thrombocytosis, Temple-Baraitser Syndrome (TMBTS), Intellectual Developmental Disorder, X-Linked, Syndromic 34 (MRXS34), etc. |
|
Nervous system disease model |
Autism, Paroxysmal Nonkinesigenic Dyskinesia (PNKD), Lissencephaly, etc. |
|
Eye disease model |
Congenital Myopia, Wet Macular Degeneration, Familial Exudative Vitreoretinopathy (FEVR), etc. |
|
Metabolic disease model |
Hypercholesterolemia, Atherosclerosis Susceptibility (ATHS), etc. |
|
Gene therapy customized model |
Various gene-regulated cells, rat and mouse models |
Type of Disease |
KO/ cKO Knockout Live Mouse |
|||
Amyotrophic Lateral Sclerosis (ALS) |
|
|
UNC13A |
CCNF |
|
OPTN |
|
|
|
|
|
NEK1 |
SETX |
|
|
PPARGC1A |
|
TRPM7 |
|
|
|
|
|
|
|
|
ERBB4 |
…… |
Surgical Models Case
At present, animal disease models are established through acquired modeling (such as surgical or drug induction) and then treated by AAV injection, which is used in the field of gene therapy research. Cyagen has a strong and efficient surgical disease model team, which can provide customers with a variety of surgical model services including but not limited to: mental diseases, cardiovascular diseases, and metabolic diseases. In addition, we are also actively developing new surgical disease models. We are proficient in a variety of modeling technologies, and can complete the tasks from AAV vector construction to in vivo injection according to the needs of gene therapy researchers, truly providing you with a one-stop service of high-quality experience.
Type |
Name |
Experimental animal |
Modeling method |
Mental diseases |
Depression |
Mouse |
Carotid artery ligation |
Menopausal depression/Osteoporosis |
Mouse |
Ovariectomy (OVX) |
|
Cardiovascular diseases |
Aortic Sclerosis |
Mouse |
Abdominal aortic constriction |
Stroke |
Mouse |
(MCAO) |
|
Myocardial ischemia |
Mouse |
Coronary artery ligation |
|
Metabolic diseases |
Liver damage |
Mouse |
Hepatic ischemia-reperfusion (HIR) |
Renal ischemia reperfusion Injury |
Mouse |
Nephrectomy |
Gene therapy vector modeling refers to local injection and systemic injection of viral vectors containing disease-causing genes to cause disease phenotypes in the whole body or part of the animal's tissues, which can be used to prepare for future treatment experiments. It is usually suitable for homozygous lethal disease models and used to model diseases in specific tissues or cells.
Request a quote now. Alternatively, you can always email animal-service@cyagen.com or call 800-921-8930 to inquire about our services or obtain a quote for your project.
Related Posts:
>> Viral Vector Design and Development